Slide 1: Q1 2026 Senzime AB (publ.) Jan-March 2026
Q1 2026 Senzime AB (publ.) Jan-March 2026
Slide 2: Q1 2026 summary
Q1 2026 summary Strengthened margins and improved cash Net Sales Rolling 12 -months KSEK 110,000 flow despite a temporary dip in the growth 100,000 curve. Full-year targets remain intact. 90,000 80,000 2026 has begun at high pace with strengthened margins and cash flow generation. But the US market
Slide 3: Spotlight US market
Spotlight US market Q1 reported revenues in local currency (kUSD) 1,800 1,600 > Sales grew 11% in USD including a 55% increase in disposable sales. 1,400 > But the USD vs SEK rate dropped with 15%, leading to 1,200 reported US sales decreasing with 5% (-2,5 MSEK). 1,000 > But growth was effected by
Slide 4: Introducing TetraGraph as-a-Service (TGaaS)
Introducing TetraGraph as-a-Service (TGaaS) • Complementary business model introduced in the US market in-line with what’s common in robotic surgery business • Subscription based where TetraGraph’s are placed and customers are charged a premium for disposables • Compelling hospital rationale shiftin
Slide 5: Converting operating rooms with our technology: key US installations last 15 months
Converting operating rooms with our technology: Selected key US TetraGraph installations last 15 months Win of the world’s leading hospital system Pacific North-West based hospital system Installation of TetraGraph monitors at multiple sites Contract includes an initial order of 65 next- generation
Slide 6: Converting operating rooms with our technology: key US installations during 2026
Converting operating rooms with our technology: Selected key US TetraGraph installations during 2026 Pacific Rim based hospital system Leading IDN Supply 2x hospitals one of the world’s largest Win of key reference hospital IDNs, encompassing a potential of more IVY League Hospital within leading US
Slide 7: Concluding the US numbers, comparing apples to apples
Concluding the US numbers, comparing apples to apples (KSEK) +48% in sales 2,500 TetraGraph as-as-a-service (6,5 MSEK) 2,500 Currency effects 14,805 Reported sales Reported sales 13,351 Demos and upgrades -2,200 Q1 25 Q1 26
Slide 8: Our global installed base of TetraGraph monitors keeps growing
Our global installed base of TetraGraph monitors keeps growing… Total delivered units of TetraGraph systems 376 (443) TetraGraphs 6,000 delivered in Q1 5,000 4,000 3,000 2,000 1,000 0 Next-Generation Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2024 2025 2026 8
Slide 9: Driving recurring sales of disposable sensors
…driving recurring sales of disposable sensors Patients monitored with the TetraGraph, accumulated 1,200,000 1,000,000 800,000 600,000 400,000 66% growth in 200,000 rolling-12 units 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2022 2023 2024 2025 2026 9
Slide 10: Product and market mix
Product and market mix Currency Reported adjusted SALES (KSEK) Q1 2026 Q1 2025 Growth Growth US 14,805 15,551 -5% 11% Net sales by region Net sales by by product group Devices/other 2,537 6,288 -60% -53% Europe Disposables 12,269 9,262 32% 55% 21% Sensors Other Europe 4,857 3,816 27% 32% 15% 76% Dev
Slide 11: First Pediatric Guidelines for Neuromuscular Monitoring
First Pediatric Guidelines for Neuromuscular Monitoring Recommending EMG-based quantitative neuromuscular monitoring on children due to its higher accuracy and reliability. 11
Slide 12: The Pediatric opportunity, and our business at-a-glance
The Pediatric opportunity, and our business at-a-glance Residual paralysis is common in children Nearly 1 in 3 children stll have residual neuromuscular block (TOF <0.9) at extubation when not quantitatively monitored (Faulk et al. 2024) Consequeneces are serious Residual neuromuscular block increas
Slide 13: The Pediatric opportunity, and our business at-a-glance
The Pediatric opportunity, and our business at-a-glance Shipped pediatric sensors (units), Q1 3x increase in sensor units, and 65 TetraGraphs 2021 2022 2023 2024 2025 delivered to pediatric OR’s in Q1 2026 13
Slide 14: Introducing the TetraCom connectivity platform
Introducing the TetraCom connectivity platform A first of its kind connectivity platform, enabling universal transmission of neuromuscular data directly into leading hospital enterprise systems such as Epic and Oracle Health TetraCom*, an AI-ready platform, seamlessly connects TetraGraph® to hospita
Slide 15: Underlying Gross Margin continues to improve
Underlying Gross Margin continues to improve Q1 2026 2025 Q1 2025 • Underlying Gross Margin continues Underlying Gross Margin 69,3% 66,7% 65,5% to improve due to pricing, lower production costs and more favorable product mix Effects on Gross Margin, relative to prior year • US tariffs and currency e
Slide 16: Operating expenses in control and reduced
Operating expenses in control and reduced Total Quarterly Operating Expenses (KSEK) 50,000 45,000 43,379 43,121 41,390 40,000 39,388 40,660 40,208 Q1 total OPEX decreased with 37,101 37,441 37,297 36,642 35,563 5% vs. Q1 in 2025 and 17,5% vs. 35,000 32,378 32,841 34,366 Q4 2025 in spite of continued
Slide 17: On path towards profitability and positive cash flow
On path towards profitability and positive cash flow Operating Cash Flow (KSEK) Q1 2023 Q1 2024 Q1 2025 Q1 2026 0 • Q1 Operating Cash Flow improved 33% to -23,029 kSEK -5,000 (-32,299), driven by optimized working capital as well as improved operating result. -10,000 • EBITDA slightly better than Q1
Slide 18: Credit facility of 50 MSEK to secure working capital needs
Credit facility of 50 MSEK to secure working capital needs • A credit facility has been issued at fair market terms by a group of existing shareholders including Crafoord and Segulah as well as DBT Capital, a part of Noba Bank Group. “ A strong vote of confidence. The facility enables us to manage p
Slide 19: Backed by a strong investor base
Backed by a strong investor base Largest shareholders Dec 31, 2025 March 31, 2026 Crafoord family and the Crafoord Foundation 25,896,551 16,5 25,896,551 16,5 Segulah-group of entities 15,870,271 10,1 15,870,271 10,1 Fredrik Rapp 11,879,088 7,6 11,879,088 7,6 Avanza Pension 8,399,437 5,3 8,192,662 5,
Slide 20: The Goals and Outlook remain intact
The Goals and Outlook remain intact The mission Outlook 2026 To safeguard every patient's journey, from anesthesia Maintain strong sales growth in-line with previous years and to recovery. We do this by developing user-friendly generate positive cash flow within the fourth quarter. precision-based m
Slide 21: Driving clinical and technological paradigm shift in the operating room
Driving clinical and technological paradigm shift in the operating room Securing precise timing of intubation, Based on >40 individualized dosing of paralytic drugs, years of science, and safe timing of extubation. extensive clinical data and over 100 patents Next-Generation
Slide 22: Used in operating rooms to increase patient safety and reduce healthcare costs
Used in operating rooms to increase patient safety and reduce healthcare costs 0% complications related to post-operative residual block, when used with reversal drugs 70% drug reduction of the cost of reversal drugs as compared to not using quantitative monitoring.
Slide 23: Key take-aways
Key take-aways Sales, MSEK 1 120 2 3 100 80 60 40 20 0 2021 2022 2023 2024 2025 HYPER GROWTH WINNING A TECHNOLOGY SHIFT BUILDING BLOCKS IN PLACE • 57% CAGR over last 5 years, • Strong demand for TetraGraph and • Guidelines in place with Q1 26 as outlier EMG-based monitoring • Backed by long-term • O
Slide 24: Safeguard every patient's journey, from anesthesia to recovery
So, join us on our mission to Safeguard every patient's journey, from anesthesia to recovery.